(October 30, 2018, 1:16 PM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on Oct. 29 affirmed that a pro se plaintiff’s withdrawal injury claim from the atypical antipsychotic Abilify is barred by a...
5th Circuit Affirms Texas’ FDA Defense Law In Abilify Withdrawal Suit
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login